#1 Clinical Trials Search in Europe

Carisbamate

Carisbamate, also known as YKP509, is an investigational drug being studied as a potential treatment for various forms of epilepsy, including Lennox-Gastaut syndrome and partial onset seizures. This article summarizes key information from clinical trials evaluating the safety, efficacy, and pharmacokinetics of carisbamate in patients with epilepsy and other conditions.

Table of Contents

What is Carisbamate?

Carisbamate, also known as YKP509 or RWJ-333369, is an investigational drug that is being studied for its potential to treat various neurological conditions, primarily epilepsy[1][2]. It is a novel compound with anticonvulsant (anti-seizure) properties, which means it helps prevent or reduce seizures[3]. Carisbamate is not yet approved for general use and is still undergoing clinical trials to determine its safety and effectiveness.

What Conditions Does Carisbamate Treat?

Carisbamate is being investigated for several conditions, including:

  • Lennox-Gastaut Syndrome (LGS): This is a severe form of epilepsy that typically begins in childhood. It is characterized by multiple types of seizures and intellectual disability[1][4].
  • Partial Onset Seizures: These are seizures that start in one area of the brain and may or may not spread to other areas[5].
  • Postherpetic Neuralgia (PHN): This is a painful condition that can occur after having shingles. It’s being studied as a potential treatment for this type of nerve pain[6].
  • Alcohol Dependence: Researchers are exploring whether carisbamate could help reduce cravings and the positive subjective effects of alcohol in people with alcohol dependence[7].

How Does Carisbamate Work?

While the exact mechanism of action is not fully understood, carisbamate is believed to work by affecting the electrical activity in the brain. As an anticonvulsant, it likely helps to stabilize nerve cell activity and prevent the abnormal firing of neurons that leads to seizures[3]. This action may also be beneficial in other neurological conditions, which is why it’s being studied for various disorders beyond epilepsy.

Dosage and Administration

Carisbamate is being studied in various formulations and dosages, depending on the condition being treated and the age of the patient. Some common forms include:

  • Oral liquid formulation (20 mg/mL)[1]
  • Tablets (various strengths, including 200 mg, 300 mg)[2]
  • Capsules (250 mg)[8]

Dosages in clinical trials have ranged from 100 mg to 1600 mg per day, often divided into two doses. The exact dosage depends on factors such as the patient’s age, weight, and the condition being treated[5][4].

Clinical Trials and Research

Carisbamate has been the subject of numerous clinical trials, including:

  • Studies in adults and children with Lennox-Gastaut Syndrome to evaluate its safety and effectiveness in reducing seizures[1][4].
  • Trials assessing its efficacy as an add-on therapy for partial onset seizures in adults[5].
  • Research on its potential to treat postherpetic neuralgia[6].
  • Investigations into its effects on alcohol cravings and consumption[7].
  • Studies to determine the best formulation and dosage, including how food affects its absorption[2].

These trials aim to establish the drug’s safety profile, determine optimal dosing, and measure its effectiveness compared to placebo or existing treatments.

Potential Side Effects

As carisbamate is still in the investigational stage, its full side effect profile is not yet established. However, clinical trials monitor for adverse events, which may include:

  • Changes in blood pressure and heart rate[7]
  • Alterations in mood or behavior
  • Gastrointestinal effects
  • Headaches
  • Dizziness or drowsiness

It’s important to note that the safety and tolerability of carisbamate are key aspects being studied in ongoing clinical trials[9].

Future Prospects

Carisbamate shows promise in treating various neurological conditions, particularly epilepsy. If proven safe and effective, it could provide a new option for patients who don’t respond well to existing treatments, especially those with difficult-to-treat conditions like Lennox-Gastaut Syndrome[4]. The drug’s potential in treating alcohol dependence also opens up possibilities for addiction treatment[7].

As research continues, more information will become available about carisbamate’s effectiveness, optimal dosing, and safety profile. Patients interested in this investigational drug should consult with their healthcare providers about the possibility of participating in clinical trials or staying informed about its development.

Aspect Details
Drug Name Carisbamate (YKP509, RWJ-333369)
Primary Conditions Studied Lennox-Gastaut Syndrome, Partial Onset Seizures
Other Conditions Studied Postherpetic Neuralgia, Alcohol Dependence
Administration Oral (tablets or liquid suspension)
Typical Adult Dosing 100-600 mg twice daily
Key Outcome Measures Seizure frequency reduction, Safety/tolerability, Pharmacokinetics, Quality of life
Study Designs Open-label, Double-blind, Placebo-controlled
Patient Populations Adults and children (as young as 2 years old in some studies)
Notable Features Studied as adjunctive therapy, Investigated different formulations

FAQ

  • What is carisbamate? Carisbamate is an investigational antiepileptic drug being studied as a potential treatment for various forms of epilepsy, including Lennox-Gastaut syndrome and partial onset seizures. It is also known by the code name YKP509.
  • What conditions is carisbamate being studied for? Carisbamate is primarily being studied for epilepsy, specifically Lennox-Gastaut syndrome and partial onset seizures. Some trials have also investigated its use for postherpetic neuralgia and alcohol dependence.
  • How is carisbamate administered? Carisbamate is typically administered orally, either as tablets or as a liquid suspension. Dosing varies by study and patient age, but common doses range from 100-600 mg twice daily for adults.
  • What are the main outcomes being measured in carisbamate trials? The main outcomes being measured include reduction in seizure frequency, safety and tolerability, pharmacokinetics (how the drug moves through the body), and quality of life measures for patients with epilepsy.
  • Are there any known side effects of carisbamate? While specific side effects are not detailed in the trial summaries provided, the studies are monitoring for adverse events, changes in vital signs, ECG readings, and laboratory values as part of assessing the drug's safety profile. More detailed safety information would come from the full trial results.

Ongoing Clinical Trials on Carisbamate

  • Study on Carisbamate for Treating Seizures in Children and Adults with Lennox-Gastaut Syndrome

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany Greece Hungary Italy Poland Portugal +1

Glossary

  • Lennox-Gastaut Syndrome (LGS): A severe form of childhood epilepsy characterized by multiple types of seizures, cognitive impairment, and a specific EEG pattern. It typically begins between ages 2-8 and often persists into adulthood.
  • Partial Onset Seizures: Seizures that begin in one area of the brain. They may remain localized or spread to other areas, potentially becoming generalized seizures.
  • Adjunctive Therapy: Additional treatment used together with the primary treatment to increase its effectiveness. In epilepsy, this often refers to adding a new medication to existing antiepileptic drugs.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Open-Label Study: A type of clinical trial where both the researchers and participants know which treatment is being administered.
  • Double-Blind Study: A type of clinical trial where neither the participants nor the researchers know who is receiving the experimental treatment and who is receiving a placebo or standard treatment.
  • Placebo: An inactive substance that looks like the drug being tested, used as a control in clinical trials to determine the true effect of the experimental treatment.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.
  • Enantiomer: One of a pair of molecular structures that are mirror images of each other but cannot be superimposed.
  • Trough Sample: A blood sample taken just before the next dose of a medication is due, used to measure the lowest concentration of the drug in the body.

References

  1. https://clinicaltrials.gov/study/NCT03731715
  2. https://clinicaltrials.gov/study/NCT04520360
  3. https://clinicaltrials.gov/study/NCT00210522
  4. https://clinicaltrials.eu/trial/study-on-carisbamate-for-treating-seizures-in-children-and-adults-with-lennox-gastaut-syndrome/
  5. https://clinicaltrials.gov/study/NCT00740623
  6. https://clinicaltrials.gov/study/NCT00492323
  7. https://clinicaltrials.gov/study/NCT02435381
  8. https://clinicaltrials.gov/study/NCT00210652
  9. https://clinicaltrials.gov/study/NCT04062981